A Multi-Center, Prospective, Open-Label, Assessor-Blinded, Randomised, Controlled, Pivotal Clinical Investigation to evaluate the Performance and Safety of 3-D Scaffold Matrix – A Class C Medical Device Bone Void Filler for Alveolar Ridge Augmentation in Implant Dentistry

EffecMed Pvt. Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年11月13日

试验速览

阶段: 2 期
状态: 招募中
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1) Patients between the age of 18 and 65 years (both inclusive) requiring treatment of oral, maxillofacial and dental intraosseous defects, such as
•a) single or two tooth extraction in mandibular or maxillary incisor or pre-molar region.
•b) dental implant is indicated and treatment planned to replace the missing tooth(s).
•c) have adequate restorative space for a dental implant-retained restoration.
•d) to refill a local bony defect due to trauma or infection.
•e) to refill a peri-implant defect due to peri implantitis.
•f) for horizontal or vertical augmentation of the mandible and maxilla.
•g) have a dehiscence of the buccal or lingual bony plate of the tooth socket extending no more than 50 percent of the total depth of the socket.
•2) Are non-smokers or former smokers. Current smokers may be included if they smoke less than 10 cigarettes per day.
•3) Written informed consent obtained before any study related activities.
•4) Communicative ability to understand the procedure and participate in the study and comply with the follow up.

排除标准

•1) Has any known diseases (not including controlled diabetes mellitus), infections or recent surgical procedures within 30 days of enrolment.
•2) Pregnant female or lactating or of childbearing potential not using acceptable methods of birth control (hormonal, barriers or abstinence.
•3) On chronic treatment (i.e. two weeks or more) with any medication known to affect oral status (e.g. phenytoin, dihydropyridine calcium antagonists, cyclosporine, and non-steroidal anti-inflammatory drugs) within one month of implantation.
•4) On concomitant anticoagulant therapy of warfarin (coumadin), clopidogrel, ticlopidine or once daily aspirin of more than 81 mg.
•5) Taking any medication or supplement known to largely influence bone metabolism, such as IV bisphosphonates, long-term history of oral bisphosphonates or chronic intake of glucocorticoids.
•6) Positive for HIV 1 or 2, Hepatitis B, or Hepatitis C.
•7) Clinically significant thyroid stimulating hormone (1.5 times of upper limit of normal)
•8) Contraindications in performing a CBCT scan.
•9) Oral malignancy.
•10) Uncontrolled diabetes mellitus.
•11) On immunosuppressive medications.
•12) Physical handicaps that would interfere with the ability to perform adequate oral hygiene.
•13) Has undergone administration of any investigational drug within 30 days of study initiation.
•14) Alcoholism or chronically drug abuse.
•15) Heavy smoker (10/cigarettes or more per day).
•16) Suffering from a known psychological disorder.
•17) Has limited mental capacity or language skills such that study information cannot be understood, informed consent cannot be obtained, or simple instructions cannot be followed.
•Local Exclusion Criteria
•1) Mandibular incisors
•2) Inadequate bone dimensions or restorative space for a dental implant
•3) Uncontrolled or untreated periodontal disease
•4) Bone defects that exclude implant restoration
•5) Patient who has a full mouth plaque level >30 % at the enrolment visit
•6) Mucosal diseases such as erosive lichen planus.
•7) History of local radiation therapy
•8) Presence of oral lesions (such as ulceration, malignancy)
•9) Severe bruxing or clenching habits
•10) Persistent intraoral infection.
•11) Past radiation therapy to the surgical site.
•12) Patients presenting clinical and radiological signs and symptoms of maxillary sinus disease
•13) Patient presents an acute endodontic lesion in the test tooth or in the neighbouring areas to the experimental procedure (sites with presence of an asymptomatic chronic lesion are eligible).

研究者

发起方

EffecMed Pvt. Ltd.

相似试验

招募中

2 期

3D Scaffold Matrix, a Class C Medical Device Bone Void Filler as a Bone Graft Substitute

CTRI/2023/10/058286EffecMed Pvt. Ltd.

进行中（未招募）

1 期

Study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line.Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third lineMedDRA version: 20.0 Level: PT Classification code 10033158 Term: Ovarian epithelial cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2013-000491-14-SKAB Science80

进行中（未招募）

不适用

Evaluation of masitinib in patients with advanced ovarian cancerAdvanced / metastatic epithelial ovarian cancer patients in secondline being refractory to first line platinum treatment or in third lineMedDRA version: 18.0Level: PTClassification code 10033158Term: Ovarian epithelial cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2013-000491-14-GBAB Science80

进行中（未招募）

不适用

Study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line.Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third lineMedDRA version: 16.1Level: PTClassification code 10033158Term: Ovarian epithelial cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2013-000491-14-FRAB Science56

进行中（未招募）

1 期

EUCTR2013-000491-14-ITAB SCIENCE